DE69634416D1 - Chinolin-derivate - Google Patents

Chinolin-derivate

Info

Publication number
DE69634416D1
DE69634416D1 DE69634416T DE69634416T DE69634416D1 DE 69634416 D1 DE69634416 D1 DE 69634416D1 DE 69634416 T DE69634416 T DE 69634416T DE 69634416 T DE69634416 T DE 69634416T DE 69634416 D1 DE69634416 D1 DE 69634416D1
Authority
DE
Germany
Prior art keywords
quinoline derivatives
quinoline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69634416T
Other languages
English (en)
Other versions
DE69634416T2 (de
Inventor
Giuseppe Arnaldo Mari Giardina
Mario Grugni
Luca Francesco Raveglia
Carlo Farino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
GlaxoSmithKline SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT95MI002461 external-priority patent/IT1276170B1/it
Priority claimed from IT96MI001689 external-priority patent/IT1307331B1/it
Application filed by GlaxoSmithKline SpA filed Critical GlaxoSmithKline SpA
Application granted granted Critical
Publication of DE69634416D1 publication Critical patent/DE69634416D1/de
Publication of DE69634416T2 publication Critical patent/DE69634416T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69634416T 1995-11-24 1996-11-22 Chinolin-derivate Expired - Fee Related DE69634416T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI952461 1995-11-24
IT95MI002461 IT1276170B1 (it) 1995-11-24 1995-11-24 Derivati chinolinici
IT96MI001689 IT1307331B1 (it) 1996-08-02 1996-08-02 Derivati chinolinici
ITMI961689 1996-08-02
PCT/EP1996/005203 WO1997021680A1 (en) 1995-11-24 1996-11-22 Quinoline derivatives

Publications (2)

Publication Number Publication Date
DE69634416D1 true DE69634416D1 (de) 2005-04-07
DE69634416T2 DE69634416T2 (de) 2005-12-29

Family

ID=26331326

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69634416T Expired - Fee Related DE69634416T2 (de) 1995-11-24 1996-11-22 Chinolin-derivate

Country Status (26)

Country Link
US (1) US6277862B1 (de)
EP (1) EP0876347B1 (de)
JP (1) JP2000501104A (de)
KR (1) KR19990071597A (de)
CN (1) CN1207730A (de)
AP (1) AP9801237A0 (de)
AR (1) AR004972A1 (de)
AT (1) ATE289994T1 (de)
BG (1) BG102558A (de)
BR (1) BR9611820A (de)
CA (1) CA2238298A1 (de)
CZ (1) CZ157998A3 (de)
DE (1) DE69634416T2 (de)
EA (1) EA002124B1 (de)
ES (1) ES2236757T3 (de)
IL (1) IL124522A0 (de)
MX (1) MX9804107A (de)
NO (1) NO311212B1 (de)
NZ (1) NZ323387A (de)
OA (1) OA11010A (de)
PL (1) PL326967A1 (de)
SK (1) SK66798A3 (de)
TR (1) TR199800924T2 (de)
TW (1) TW353066B (de)
UY (1) UY24733A1 (de)
WO (1) WO1997021680A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219131B (hu) * 1991-10-18 2001-02-28 Monsanto Co. Módszer és fungicid készítmény növények torsgombabetegségének gátlására és a hatóanyagok
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US7037922B1 (en) * 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
EP1165542B1 (de) 1999-03-29 2003-08-20 Neurogen Corporation 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
ATE313539T1 (de) * 2001-04-11 2006-01-15 Glaxosmithkline Spa Chinolin-4-carboxamidderivate als nk-3 und nk-2 rezeptor antagonisten
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN100589839C (zh) 2003-01-28 2010-02-17 艾恩伍德医药品股份有限公司 多肽及包含多肽的药物组合物
GB0303086D0 (en) 2003-02-11 2003-03-19 Merck Sharp & Dohme New compounds
GB0419192D0 (en) 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
JP2008519761A (ja) * 2004-11-09 2008-06-12 スミスクライン ビーチャム コーポレーション グリコーゲンホスホリラーゼ阻害化合物およびその医薬組成物
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
JP2009504641A (ja) * 2005-08-11 2009-02-05 アストラゼネカ・アクチエボラーグ Ｎｋ−３受容体の調節剤としてのアルキルピリジルキノリン
AR057130A1 (es) 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
TW200804288A (en) * 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2197845A1 (de) * 2007-09-28 2010-06-23 GlaxoSmithKline LLC Glycogenphosphorylasehemmerverbindung und pharmazeutische zusammensetzung daraus
EP2195287A1 (de) * 2007-09-28 2010-06-16 GlaxoSmithKline LLC Glycogenphosphorylasehemmerverbindung und pharmazeutische zusammensetzung daraus
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
HUE036405T2 (hu) 2008-12-31 2018-07-30 Ardelyx Inc Vegyületek és módszerek az NHE-közvetített (Na+/H+ cserével mûködõ) antiport gátlására folyadékretencióval vagy túlzott sómennyiség jelenlétével és a gyomor-bél traktus zavaraival összefüggõ rendellenességek kezelésében
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2880338A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
SI2983667T1 (sl) 2013-04-12 2019-09-30 Ardelyx, Inc. Spojine za vezavo NHE3 in metode za zaviranje transporta fosfata
EP2986293A1 (de) 2013-04-19 2016-02-24 Astrazeneca AB Nk3-rezeptorantagonistverbindung (nk3rai zur verwendung in einem verfahren für die behandlung von polyzystischem ovarialsyndrom (pcos)
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
EP3565808A1 (de) 2017-01-09 2019-11-13 Ardelyx, Inc. Verbindungen zur behandlung erkrankungen des magen-darm-traktes
US11147884B2 (en) 2017-01-09 2021-10-19 Ardelyx, Inc. Inhibitors of NHE-mediated antiport

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2538388B1 (fr) * 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
JPS6399057A (ja) * 1986-06-27 1988-04-30 Nippon Shinyaku Co Ltd グリシン誘導体
ES2227769T3 (es) * 1994-05-27 2005-04-01 Glaxosmithkline S.P.A. Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina.
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
SK66798A3 (en) 1999-01-11
UY24733A1 (es) 2001-08-27
MX9804107A (es) 1998-09-30
ES2236757T3 (es) 2005-07-16
CN1207730A (zh) 1999-02-10
NZ323387A (en) 2000-02-28
OA11010A (en) 2003-03-06
BG102558A (bg) 1999-03-31
IL124522A0 (en) 1998-12-06
DE69634416T2 (de) 2005-12-29
EP0876347A1 (de) 1998-11-11
EP0876347B1 (de) 2005-03-02
TR199800924T2 (xx) 1998-08-21
US6277862B1 (en) 2001-08-21
ATE289994T1 (de) 2005-03-15
JP2000501104A (ja) 2000-02-02
AR004972A1 (es) 1999-04-07
AP9801237A0 (en) 1998-06-30
NO982331L (no) 1998-07-22
NO311212B1 (no) 2001-10-29
PL326967A1 (en) 1998-11-09
CA2238298A1 (en) 1997-06-19
BR9611820A (pt) 1999-07-13
WO1997021680A1 (en) 1997-06-19
EA199800477A1 (ru) 1998-12-24
CZ157998A3 (cs) 1998-12-16
EA002124B1 (ru) 2001-12-24
TW353066B (en) 1999-02-21
KR19990071597A (ko) 1999-09-27
NO982331D0 (no) 1998-05-22

Similar Documents

Publication Publication Date Title
ATE289994T1 (de) Chinolin-derivate
DE69611361T2 (de) Chinazolin-derivate
DE69522717D1 (de) Chinazolinderivate
NO974103D0 (no) Arylsulfonylaminohydroksamsyre-derivater
DE69610698D1 (de) Chinazolin-derivate
PT833828E (pt) Derivados de rapamicina
BR9611834A (pt) Derivados de oximetóxi-3-aril-pirona
NO964667D0 (no) Purin-6-on-derivater
ATE201199T1 (de) Benzo(g)chinolinderivate
ATE199150T1 (de) Diphenylmethylenpiperidin-derivate
DE69601527T2 (de) Pyrrolylbenzimidazol-Derivate
ATA100695A (de) Prothrombin-derivate
ATE240307T1 (de) Diarylalkenylamin-derivate
DE69627830D1 (de) Pyrazol-derivate
DE59607054D1 (de) 4-Amino-benzoylguanidin-Derivate
ATE177102T1 (de) Chromanderivate
DE59610106D1 (de) Fluorbenzylether-Derivate
DE69624122D1 (de) Aza-anthracyclinone-derivate
BR9603508A (pt) Derivados de alquenil-benzoilguanidina
ATE202088T1 (de) 4-mercapto-benzoylguanidin-derivate
DE69620514T2 (de) 5-aminoflavon-derivate
ATA45796A (de) Lysin-prolin-derivate
ITMI950495A0 (it) Derivati chinolinici
ITMI950494A0 (it) Derivati chinolinici
BR9603733A (pt) Derivados de cloropiridilcarbonila

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee